Novo Nordisk (NVO) Webpage traffic Statistics 2025

752,000 12.3%

1M 12.3% 3M 10.8%

Est. monthly webpage visitors.

Similar companies

Company		Webpage traffic
	Johnson & Johnson JNJ	2,166,000 15.1%
	Eli Lilly and Company LLY	6,733,000 27.7%
	Pfizer PFE	1,937,000 46.9%
	Astrazeneca AZN	667,000 2.6%
	AbbVie ABBV	1,047,000 1.7%

Month over Month

Est. monthly webpage visitors.

Apr 2025	752,000	12.3%
Mar 2025	857,000	2.7%
Feb 2025	881,000	4.5%
Jan 2025	843,000

How many visits novonordisk.com?

Novo Nordisk has an estimate of 752,000 visitors to novonordisk.com in April. This is down since March.

Analyzing Webpage traffic, how is Novo Nordisk performing compared to its industry peers?

Novo Nordisk underperforms its industry peers when it comes to Webpage traffic, ranking in the 11th percentile.

Why is it important to track website traffic for Novo Nordisk?

By staying updated on webpage traffic for Novo Nordisk, investors can gain valuable insights into the company's digital performance, customer engagement and acquisition, and overall effectiveness of its online presence. Higher traffic can indicate greater visibility and potential customer exposure and a lower or decreasing traffic can indicate challenges with retaining customers.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.